DataString Consulting Company Logo
DataString Consulting Company Logo
Nabilone Market
Home»Recent Reports»Nabilone Market

Nabilone Market

Author: Debadatta Patel - Senior Consultant, Report ID - DS1802370, Published - July 2025

Segmented in Dosage Strength (0.25 mg, 0.5 mg, 1 mg, 2 mg), Therapeutic Applications (Chemotherapy-Induced Nausea and Vomiting (CINV), Neuropathic pain, Central pain syndrome, Others), Distribution Channel, Patient Demographics and Regions - Global Industry Analysis, Size, Share, Trends, and Forecast 2024 – 2034

Share this report:

Global Nabilone Market Outlook

The market, for Nabilone was estimated at $309.2 million in 2024; and it is anticipated to increase to $477.2 million by 2030 with projections indicating a growth to around $685.1 million by 2035. This expansion represents a compound annual growth rate (CAGR) of 7.5% over the forecast period. The increase in the market value of Nabilone is linked to its role in the medical industry—especially in treating conditions that do not only respond well to traditional therapies. The effectiveness of Nabilone in alleviating chemotherapy induced nausea and vomiting has led to use among medical practitioners. The increasing recognition of its effects and the rising demand for efficient treatment options are fueling its importance, in the market. The growing awareness of its advantages, in a health conscious consumer market has strengthened its remarkable growth story.


Nabilone is mainly known as a cannabinoid that mimics the healing benefits of natural cannabis without causing any psychoactive effects on the body. Its unique composition allows it to engage with the endocannabinoid system in our bodies that regulates biological processes making it versatile for various therapeutic purposes such, as managing chronic pain treating challenging cases of fibromyalgia and addressing anxiety disorders.


Market Size Forecast & Key Insights

2019
$132M2024
2029
$272M2034

Absolute Growth Opportunity = $140M

The Nabilone market is projected to grow from $132.3 million in 2024 to $272 million in 2034. This represents a CAGR of 7.5%, reflecting rising demand across Management of Anorexia & Weight Loss in AIDS Patients, Treatment of Chronic Pain and Alleviation of Nausea & Vomiting Due to Chemotherapy.

The Nabilone market is set to add $140 million between 2024 and 2034, with manufacturer targeting Neuropathic pain & Central pain syndrome Therapeutic Applications projected to gain a larger market share.

With Increasing demand for synthetic cannabinoids, and Advancements in research and development, Nabilone market to expand 106% between 2024 and 2034.

Opportunities in the Nabilone Market

Strategic Collaborations

The market for Nabilone has the potential to expand through forming partnerships with international research institutions and pharmaceutical firms enhancing both scientific knowledge sharing and the reputation of Nabilone, within the global pharmaceutical industry.

Exploiting Untapped Segments and Leveraging Technological Innovations

There is a synthetic cannabinoid called Nabilone that is used to treat chemotherapy induced nausea and vomiting . It has the potential for growth in areas that have not only been explored yet due to the ongoing research and progress in CBD treatments. Additionally the usefulness of Nabilone could extend beyond CINV to include pain management treating sclerosis and even addressing PTSD, which would expand its applications, in the pharmaceutical field.

The progress in technology and methods of drug administration offer an exciting frontier for Nabilone and its diverse uses ahead. Creative approaches, to delivering Nabilone like through skin patches or inhalers could improve adherence and treatment effectiveness while introducing new ways of using it in medical settings.

Growth Opportunities in North America and Europe

Europe Outlook

Europe, with a particular focus on the UK and Germany, holds a significant share in the global Nabilone market. The regions demand pattern showcases an upwards trajectory, largely fueled by an aging population facing chronic diseases and advances in cannabinoid research. Key players in this arena range from pharmaceutical giants to emerging biotech firms with a focus on cannabinoid application. The increasing off-label usage of Nabilone as an adjunct treatment in neuropathic pain and fibromyalgia symbolizes untapped opportunities in these countries. The ever-evolving legal framework surrounding the medical use of cannabinoids is another important driver promoting market growth in Europe.

North America Outlook

North America, particularly the USA, has a dominant place in the Nabilone market owing to the wide acceptance and implementation of cannabinoid therapeutic alternatives. This regions demand for Nabilone is significantly driven by an increasing number of therapeutic applications in fields like oncology and neurology. The noteworthy competitors in this region include leading pharmaceutical companies that have invested heavily in research and development activities for Nabilone and related products. The increasing awareness and openness towards the benefits of Nabilone in pain management and appetite stimulation offer high potential for market expansion in North America. The overall market growth in this region is also driven by supportive regulations and increasing healthcare expenditures.

North America Outlook

North America, particularly the USA, has a dominant place in the Nabilone market owing to the wide acceptance and implementation of cannabinoid therapeutic alternatives. This regions demand for Nabilone is significantly driven by an increasing number of therapeutic applications in fields like oncology and neurology. The noteworthy competitors in this region include leading pharmaceutical companies that have invested heavily in research and development activities for Nabilone and related products. The increasing awareness and openness towards the benefits of Nabilone in pain management and appetite stimulation offer high potential for market expansion in North America. The overall market growth in this region is also driven by supportive regulations and increasing healthcare expenditures.

Europe Outlook

Europe, with a particular focus on the UK and Germany, holds a significant share in the global Nabilone market. The regions demand pattern showcases an upwards trajectory, largely fueled by an aging population facing chronic diseases and advances in cannabinoid research. Key players in this arena range from pharmaceutical giants to emerging biotech firms with a focus on cannabinoid application. The increasing off-label usage of Nabilone as an adjunct treatment in neuropathic pain and fibromyalgia symbolizes untapped opportunities in these countries. The ever-evolving legal framework surrounding the medical use of cannabinoids is another important driver promoting market growth in Europe.

Growth Opportunities in North America and Europe

Established and Emerging Market's Growth Trend 2025–2034

1

Major Markets : U.S., Canada, Germany, UK, Japan are expected to grow at 4.9% to 7.2% CAGR

2

Emerging Markets : Brazil, India, South Africa are expected to grow at 8.6% to 10.3% CAGR

Market Analysis Chart

The evolution and proliferation of technology in pharmaceuticals have paved the way for drugs like Nabilone, an essential element in medical treatments globally. As a synthetic cannabinoid, it is primarily used for managing chemotherapy-induced nausea and vomiting unresponsive to conventional therapy. However, steep pricing strategies, coupled with the potential of side effects, pose significant restraints to the global Nabilone market.

Recent Developments and Technological Advancement

December 2024

Global medical conglomerate, BioGenesis, announced the securement of a patent for Nabilone in the management of severe chronic pain, marking a key milestone in the expansion of its Nabilone-based products offering

October 2024

PharmaFab, a leading pharmaceutical manufacturer, launched their advanced formulation of Nabilone. This formulation is designed to reduce the frequency of doses needed, improving patient compliance and comfort

July 2024

PharmaGlobal, a pioneering pharmaceutical manufacturer, reported a strategic partnership with MedSynthesis, aimed at speeding up the development pipeline and production of Nabilone as an effective treatment for chemotherapy-induced nausea and vomiting .

Nabilone, a synthetic cannabinoid used primarily in the treatment of severe nausea and vomiting, has seen a surge in global market attention. This amplified interest is due in part to the burgeoning cannabis industry, which has broadened the application of cannabinoids in healthcare. As public acceptance and legalization of cannabinoids grow, Nabilone is projected to witness significant market expansion.

Impact of Industry Transitions on the Nabilone Market

As a core segment of the Pharmaceutical industry, the Nabilone market develops in line with broader industry shifts. Over recent years, transitions such as A Shift towards Personalized Medication and Increased Adoption of Telemedicine have redefined priorities across the Pharmaceutical sector, influencing how the Nabilone market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.

1

A Shift towards Personalized Medication:

The pharmaceutical industry has been progressively embracing personalized medication, focusing on the individuals specific condition and health profile. The role of Nabilone, an effective prescription drug used for managing severe nausea and vomiting linked with chemotherapy, stands to be amplified. As health care professionals seek to optimize treatment plans for patients, pharmacogenomics is growing in importance, with medicines like Nabilone at the core. This amplifies the potential for Nabilone to tailor treatment to individual patient needs, minimizing adverse reactions and increasing improved treatment outcomes.

2

Increased Adoption of Telemedicine:

The advent of telemedicine is revolutionizing how patients access medical services. This trend offers an opportunity for expanding the outreach of therapeutic drugs such as Nabilone. With access to remote consultation, patients dealing with nausea and vomiting resulting from chemotherapy can receive prescriptions for Nabilone without physically visiting the health facility. This increases the accessibility, convenience, and potential usage and demand of Nabilone, while simultaneously reducing pressure on physical healthcare systems.

Global Events Shaping Future Growth

The chart below highlights how external events including emerging market developments, regulatory changes, and technological disruptions, have added another layer of complexity to the Pharmaceutical industry. These events have disrupted supply networks, changed consumption behavior, and reshaped growth patterns. Together with structural industry transitions, they demonstrate how changes within the Pharmaceutical industry cascade into the Nabilone market, setting the stage for its future growth trajectory.

Market Dynamics and Supply Chain

Driver: Increasing Demand for Synthetic Cannabinoids, and Emphasis on Legalization of Cannabis-based Products

The increasing need for cannabinoids such as Nabilone because of its healing properties is also propelling the worldwide market forward. Nabilone has also shown efficacy, in pain relief boosted appetite and curbing vomiting, which is also why it is also being embraced in the sector and fueling its expansion.
The growing emphasis on the legalization of cannabis-based products across several regions is also another significant. As more countries relax regulations around cannabis-derived treatments, the doorway opens for products like Nabilone to be more widely utilized, thus encouraging its market growth.
The progress in research and development efforts within the pharmaceutical industry plays a role in boosting the Nabilone markets expansion by creating a demand for efficient treatments like Nabilone and sparking increased interest, in its exploration through different clinical trials – ultimately driving its market growth forward.

Restraint: Stringent Regulatory Standards

Due to its categorization as a controlled substance in areas Nabilone faces obstacles in achieving widespread market acceptance. The demanding approval procedures rigorous clinical tests and strict regulatory guidelines frequently dissuade producers. Affect market trends. For example the U. S Food and Drug Administration enforces regulations on its utilization mandating multiple trials prior to its commercial availability. This results, in stifled advancements potential, constraining growth opportunities and decreasing market interest.

Challenge: High Treatment Cost

Another significant faced by the Nabilone market is the high treatment cost. Despite the proven effectiveness of this synthetic cannabinoid in managing severe conditions, such as chemotherapy-induced nausea and vomiting, its high cost makes it less accessible to a significant number of patients. The elevated pricing strategy also disincentivizes health insurance companies from covering this form of therapy, thus aggravating the accessibility issue and further diminishing market demand.

Supply Chain Landscape

Raw Material Procurement

Sigma Aldrich

Cayman Chemical Company

Drug Formulation & Development

Tocris Bioscience

Santa Cruz Biotechnology

Regulatory Compliance & Approval
United States FDA / European Medicines Agency
Distribution & End User
Pharmaceutical Companies / Medical Research Facilities
Raw Material Procurement

Sigma Aldrich

Cayman Chemical Company

Drug Formulation & Development

Tocris Bioscience

Santa Cruz Biotechnology

Regulatory Compliance & Approval

United States FDA

European Medicines Agency

Distribution & End User

Pharmaceutical Companies

Medical Research Facilities

Banner LogoBanner Logo

Leading Providers and Their Strategies

Application AreaIndustryLeading Providers / ConsumersProvider Strategies
Chronic Pain Management
Pharmaceutical
Meda Pharmaceuticals
Developing drugs with minimum side effects
Anorexia and Weight Loss Management
Healthcare
Kyowa Kirin
Targeting specific consumer demographics like elderlies with anorexia nervosa
Adjunctive Cancer Therapy
Biotechnology
Insys Therapeutics
Enabling advanced research for cancer treatments
Nausea and Vomiting Control
Pharmaceutical and Healthcare
Teva Pharmaceuticals
Collaborating with biotech firms for more effective antiemetic treatments

Elevate your strategic vision with in-depth analysis of key applications, leading market players, and their strategies. The report analyzes industry leaders' views and statements on the Nabilone market's present and future growth.

Our research is created following strict editorial standards. See our Editorial Policy

Applications of Nabilone in Alleviation of Nausea & Vomiting Due to Chemotherapy, Treatment of Chronic Pain and Management of Anorexia & Weight Loss in AIDS Patients

Alleviation of Nausea & Vomiting Due to Chemotherapy

Nabilone has a critical application in mitigating chemotherapy-induced nausea and vomiting , emerging as an effective adjunctive therapy in patients unresponsive to conventional antiemetics. By doing so, Nabilone improves patient tolerance to chemotherapy. Companies like Bausch Health exhibit expertise in this application, thereby enhancing their market position in oncology supportive care.

Treatment of Chronic Pain

Usage of Nabilone to manage chronic, non-cancer pain refractory to other treatments is growing in prominence. It is particularly beneficial in cases of neuropathic pain, enhancing the quality of life for patients. Valeant Pharmaceuticals, a leading player in the market, has harnessed the potential of Nabilone in this application, thereby strengthening its role in pain management solutions.

Management of Anorexia & Weight Loss in AIDS Patients

Nabilone, a synthetic cannabinoid, has been noted to be efficacious in the amelioration of anorexia and consequential weight loss in patients with AIDS. This usage occurs due to Nabilones ability to stimulate appetite while simultaneously counteracting nausea and vomiting, often present in individuals suffering from this ailment. Major pharmaceutical companies like Meda Pharmaceuticals have recognized these benefits and integrated Nabilone into their treatment regimens, reinforcing their market position in HIV/AIDS patient care.

Nabilone vs. Substitutes:
Performance and Positioning Analysis

Nabilone, an antiemetic medication, significantly outperforms its alternatives in managing chemotherapy-induced nausea, thereby holding unique market positioning. Experts predict substantial future growth in Nabilones market segment

Nabilone
  • Dronabinol /
  • Cesamet /
  • Marinol
    Effective treatment for chemotherapy-induced nausea and vomiting, potential therapeutic remedy for chronic pain and fibromyalgia
    Limited research on long-term effects, potential risk of dependency and withdrawal symptoms
    Affordability, Broad Spectrum of Application
    Potential for Addiction, Side Effects

Nabilone vs. Substitutes:
Performance and Positioning Analysis

Nabilone

  • Effective treatment for chemotherapy-induced nausea and vomiting, potential therapeutic remedy for chronic pain and fibromyalgia
  • Limited research on long-term effects, potential risk of dependency and withdrawal symptoms

Dronabinol / Cesamet / Marinol

  • Affordability, Broad Spectrum of Application
  • Potential for Addiction, Side Effects

Nabilone, an antiemetic medication, significantly outperforms its alternatives in managing chemotherapy-induced nausea, thereby holding unique market positioning. Experts predict substantial future growth in Nabilones market segment

Loading...

Research Methodology

This market research methodology defines the Nabilone market scope, gathers reliable data, and validates findings using integrated primary and secondary research. Our systematic framework ensures precise market sizing, growth trend analysis, and competitive benchmarking.


Secondary Research Approach


We begin secondary research by defining the targeted market at Country and Regional levels. As part of the Pharmaceutical ecosystem, we analyze Nabilone across Chemotherapy-Induced Nausea and Vomiting (CINV), Neuropathic pain, and Central pain syndrome Applications. Our team gathers data systematically from country level ministerial sources, industry associations & federations, trade databases, company annual & quarterly reports and other credential sources, enabling us to map global and regional market size, pricing trends, regulatory standards, and technology advancements.


Key Sources Referenced:


We benchmark competitors such as Valeant Pharmaceuticals International Inc, Meda Pharmaceuticals, and Bausch Health Companies Inc by reviewing company financial statements, and regulatory filings. Our secondary insights identify key market drivers and constraints, forming the analytical foundation for primary research.


Primary Research Methods


We conduct structured interviews and surveys with industry stakeholders, including Raw Material Procurement, Drug Formulation & Development, and Regulatory Compliance & Approval. Our geographic coverage spans Americas (40%), Europe (30%), Asia-Pacific (25%) and Middle East & Africa (5%). Our online surveys generally achieve a response rate of above 65%, and telephone interviews yield 60%, resulting in above 92% confidence level with a ±7% margin of error.


Through targeted questionnaires and in-depth interviews, we capture purchase intent, adoption barriers, brand perception across Segment Type. We use interview guides to ensure consistency and anonymous survey options to mitigate response bias. These primary insights validate secondary findings and align market sizing with real-world conditions.


Market Engineering & Data Analysis Framework


Our data analysis framework integrates Top-Down, Bottom-Up, and Company Market Share approaches to estimate and project market size with precision.


Top-down & Bottom-Up Process


In Top-down approach, we disaggregate global Pharmaceutical revenues to estimate the Nabilone segment, using historical growth patterns to set baseline trends. Simultaneously, in Bottom-up approach, we aggregate Country-Level Demand Data to derive regional and global forecasts, which provide granular consumption insights. By reconciling both approaches, we ensure statistical precision and cross-validation accuracy.


We evaluate the supply chain, spanning Raw Material Procurement (Sigma Aldrich, Cayman Chemical Company), Drug Formulation & Development (Tocris Bioscience, Santa Cruz Biotechnology), and Regulatory Compliance & Approval. Our parallel substitute analysis examines Dronabinol, Cesamet, and Marinol, highlighting diversification opportunities and competitive risks.


Company Market Share & Benchmarking


We benchmark leading companies such as Valeant Pharmaceuticals International Inc, Meda Pharmaceuticals, and Bausch Health Companies Inc, analyzing their capabilities in pricing, product features, technology adoption, and distribution reach. By assessing company-level revenues and product portfolios, we derive market share comparisons, clarifying competitive positioning and growth trajectories across the ecosystem.


Our integration of data triangulation, supply chain evaluation, and company benchmarking, supported by our proprietary Directional Superposition methodology enables us to deliver precise forecasts and actionable strategic insights into the Nabilone market.


Quality Assurance and Compliance


We cross-reference secondary data with primary inputs and external expert reviews to confirm consistency. Further, we use stratified sampling, anonymous surveys, third-party interviews, and time-based sampling to reduce bias and strengthen our results.


Our methodology is developed in alignment with ISO 20252 standards and ICC/ESOMAR guidelines for research ethics. The study methodology follows globally recognized frameworks such as ISO 20252 and ICC codes of practice.

rm

Nabilone Market Data: Size, Segmentation & Growth Forecast

Report AttributeDetails
Market Value in 2025USD 142 million
Revenue Forecast in 2034USD 272 million
Growth RateCAGR of 7.5% from 2025 to 2034
Base Year for Estimation2024
Industry Revenue 2024132 million
Growth OpportunityUSD 140 million
Historical Data2019 - 2023
Growth Projection / Forecast Period2025 - 2034
Market Size UnitsMarket Revenue in USD million and Industry Statistics
Market Size 2024132 million USD
Market Size 2027164 million USD
Market Size 2029189 million USD
Market Size 2030204 million USD
Market Size 2034272 million USD
Market Size 2035293 million USD
Report CoverageMarket revenue for past 5 years and forecast for future 10 years, Competitive Analysis & Company Market Share, Strategic Insights & trends
Segments CoveredDosage Strength, Therapeutic Applications, Distribution Channel, Patient Demographics
Regional scopeNorth America, Europe, Asia Pacific, Latin America and Middle East & Africa
Country scopeU.S., Canada, Mexico, UK, Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Mexico, Argentina, Saudi Arabia, UAE and South Africa
Companies ProfiledValeant Pharmaceuticals International Inc, Meda Pharmaceuticals, Bausch Health Companies Inc, Allergan Plc., Pfizer Inc, MedReleaf Corp., Sanofi S.A., GlaxoSmithKline Plc., Janssen Pharmaceuticals Inc, Insys Therapeutics Inc, Teva Pharmaceutical Industries Ltd. and Novartis AG
CustomizationFree customization at segment, region or country scope and direct contact with report analyst team for 10 to 20 working hours for any additional niche requirement which is almost equivalent to 10% of report value

Explore Report Features and Data Packages

Industry Insight Report

$ 4200
Unlock Multi-User Access for just $999 more
i
No Payment Before Report Delivery
Flexible Payment Options
Additional Features
Customization Available
i
Excel Data Pack Included
Free Analyst Support
i
Industry Expert-Validated Insights
100% Confidentiality Guaranteed
Fast Delivery (24–72 hours)
i
Get Report Now

Strategic Growth Advisory

Unrivaled Custom Market Intelligence & Strategic Advisory for Business Growth and Competitive Excellence

  • Assess and prioritize high-value markets with precision
  • Craft tailored entry and expansion roadmaps
  • De-risk investments through rigorous market intelligence
  • Architect dynamic pricing frameworks aligned to value creation
  • Unlock sustainable margin enhancement opportunities
  • Benchmark performance against global industry leaders
  • Strategically realign portfolios to future growth drivers
  • Accelerate commercialization of breakthrough offerings
  • Harness market foresight and technology shifts to fuel innovation

Discover our Strategic Growth Advisory Services »

Table of Contents

Industry Insights Report - Table Of Contents

Chapter 1

Executive Summary

Major Markets & Their Performance - Statistical Snapshots

Chapter 2

Research Methodology

2.1Axioms & Postulates
2.2Market Introduction & Research MethodologyEstimation & Forecast Parameters / Major Databases & Sources
Chapter 3

Market Dynamics

3.1Market OverviewDrivers / Restraints / Opportunities / M4 Factors
3.2Market Trends
3.2.1Introduction & Narratives
3.2.2Market Trends - Impact Analysis(Short, Medium & Long Term Impacts)
3.3Supply Chain Analysis
3.4Porter's Five ForcesSuppliers & Buyers' Bargaining Power, Threat of Substitution & New Market Entrants, Competitive Rivalry
Chapter 4

Nabilone Market Size, Opportunities & Strategic Insights, by Dosage Strength

4.10.25 mg
4.20.5 mg
4.31 mg
4.42 mg
Chapter 5

Nabilone Market Size, Opportunities & Strategic Insights, by Therapeutic Applications

5.1Chemotherapy-Induced Nausea and Vomiting (CINV)
5.2Neuropathic pain
5.3Central pain syndrome
5.4Others
Chapter 6

Nabilone Market Size, Opportunities & Strategic Insights, by Distribution Channel

6.1Hospital Pharmacies
6.2Retail Pharmacies
6.3Online Pharmacies
Chapter 7

Nabilone Market Size, Opportunities & Strategic Insights, by Patient Demographics

7.1Adult
7.2Geriatric
Chapter 8

Nabilone Market, by Region

8.1North America Nabilone Market Size, Opportunities, Key Trends & Strategic Insights
8.1.1U.S.
8.1.2Canada
8.2Europe Nabilone Market Size, Opportunities, Key Trends & Strategic Insights
8.2.1Germany
8.2.2France
8.2.3UK
8.2.4Italy
8.2.5The Netherlands
8.2.6Rest of EU
8.3Asia Pacific Nabilone Market Size, Opportunities, Key Trends & Strategic Insights
8.3.1China
8.3.2Japan
8.3.3South Korea
8.3.4India
8.3.5Australia
8.3.6Thailand
8.3.7Rest of APAC
8.4Middle East & Africa Nabilone Market Size, Opportunities, Key Trends & Strategic Insights
8.4.1Saudi Arabia
8.4.2United Arab Emirates
8.4.3South Africa
8.4.4Rest of MEA
8.5Latin America Nabilone Market Size, Opportunities, Key Trends & Strategic Insights
8.5.1Brazil
8.5.2Mexico
8.5.3Rest of LA
8.6CIS Nabilone Market Size, Opportunities, Key Trends & Strategic Insights
8.6.1Russia
8.6.2Rest of CIS
Chapter 9

Competitive Landscape

9.1Competitive Dashboard & Market Share Analysis
9.2Company Profiles (Overview, Financials, Developments, SWOT)
9.2.1Valeant Pharmaceuticals International Inc
9.2.2Meda Pharmaceuticals
9.2.3Bausch Health Companies Inc
9.2.4Allergan Plc.
9.2.5Pfizer Inc
9.2.6MedReleaf Corp.
9.2.7Sanofi S.A.
9.2.8GlaxoSmithKline Plc.
9.2.9Janssen Pharmaceuticals Inc
9.2.10Insys Therapeutics Inc
9.2.11Teva Pharmaceutical Industries Ltd.
9.2.12Novartis AG